Market Newsdesk

TAIPEI, Taiwan and MILPITAS, Calif., July 08, 2021 (GLOBE NEWSWIRE) — Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion” or the “Company”), a global leader in NAND flash controllers for solid state storage devices, announces that based on its preliminary second quarter financial results, revenue is expected to grow approximately 20% sequentially, well in excess of the original 5% to 10% guidance range which the company issued on May 6, 2021. Gross margin (non-GAAP) is expected to be at least half a percentage point above the high-end of the company’s original 48.0% to 50.0% guidance range.

The Company will release its second quarter 2021 financial results after the market closes on July 29, 2021 and will host a conference call on July 30 at 8:00 a.m. Eastern Time. Participants must pre-register using the link below in order to participate in the live call.  

(Speakers)
Wallace Kou, President & CEO
Riyadh Lai, CFO

CONFERENCE CALL DETAILS:

Participants must register in advance to join the conference using the link provided below and should dial in 10 minutes prior to the call start time. Conference access information (including dial-in numbers, the passcode, and a unique access pin) will be provided in the email received upon registration.

Participant Online Registration:
http://apac.directeventreg.com/registration/event/9533307

This call will be webcasted on the Company’s website at www.siliconmotion.com.

ABOUT SILICON MOTION:
We are the global leader in supplying NAND flash controllers for solid state storage devices.  We supply more SSD controllers than any other company in the world for servers, PCs and other client devices and are the leading merchant supplier of eMMC and UFS embedded storage controllers used in smartphones, IoT devices and other applications.  We also supply customized high-performance hyperscale data center and specialized industrial and automotive SSD solutions.  Our customers include most of the NAND flash vendors, storage device module makers and leading OEMs.  For further information on Silicon Motion, visit us at www.siliconmotion.com.

FORWARD-LOOKING STATEMENTS:

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward-looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to the unpredictable volume and timing of customer orders, which are not fixed by contract but vary on a purchase order basis; the loss of one or more key customers or the significant reduction, postponement, rescheduling or cancellation of orders from one or more customers; general economic conditions or conditions in the semiconductor or consumer electronics markets; the effects on our business and our customer’s business taking into account the ongoing US-China tariffs and trade disputes together with the uncertainties associated with the ongoing global outbreak of COVID-19; decreases in the overall average selling prices of our products; changes in the relative sales mix of our products; changes in our cost of finished goods; the payment, or non-payment, of cash dividends in the future at the discretion of our board of directors and any announced planned increases in such dividends; changes in our cost of finished goods; the availability, pricing, and timeliness of delivery of other components and raw materials used in the products we sell given the current raw material supply shortages being experienced in our industry; our customers’ sales outlook, purchasing patterns, and inventory adjustments based on consumer demands and general economic conditions; any potential impairment charges that may be incurred related to businesses previously acquired or divested in the future; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 20-F filed on May 12, 2021. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.   

Aviation business comprises the firm’s integrated lending and leasing platforms, including PK AirFinance and Merx


Aviation

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”) today announced that entities, clients and funds managed by its affiliates completed approximately $1 billion in aircraft-related origination volume during the second quarter, the most active quarter on record since Apollo began programmatically investing in aircraft assets nearly a decade ago.

“We see a growing and sustained need for scaled providers of capital solutions, and believe platforms like ours that combine in-depth technical knowledge with strong origination and structuring expertise are particularly well placed to help airlines and lessors solve their most pressing challenges,” said Gary Rothschild, Head of Aviation at Apollo and CEO of Merx. “We view the significant momentum shown in the quarter as a testament to the strength of our integrated platform, flexible capital and ability to act as a solutions provider to the global airline industry as it continues to manage through the significant disruption from the last year.”

During the quarter, Apollo completed fundraising for its inaugural dedicated aviation finance offering, Navigator Aviation Fund I (“Navigator”). Navigator provides exposure to directly sourced private deals across diverse opportunity set of aircraft types, vintages, airlines and jurisdictions. Since inception, Navigator has committed to 33 aircraft across 15 different operators.

Also closed in the quarter was issuance of $540 million of secured notes by MAPS 2021-1 Trust (“MAPS”). MAPS is an aircraft asset-backed securitization, serviced by Merx, financing a high-quality and diverse portfolio of 20 Airbus and Boeing aircraft valued at approximately $620 million. The portfolio features 18 narrow body aircraft and two wide body freighters, with a weighted average age of 5.8 years overall and 4.3 years excluding freighters, and a weighted average lease term of 8.4 years. The equity in the ABS was retained by Navigator.

Apollo’s aircraft and aviation financing business has consistently and significantly grown for nearly a decade, today consisting of more than 50 professionals exclusively focused on aviation and led by senior executives highly experienced in aviation finance, investments, and structuring.

In 2012, Apollo established Merx, a global aircraft leasing, management, and finance company that operates in New York, Dublin and Singapore. And in 2019, Apollo and Athene Holding Ltd. acquired PK AirFinance, one of the world’s largest aviation-focused lenders which primarily originates senior secured loans. Combined, the Apollo aviation platform currently finances over 360 commercial aircraft and more than 60 engines.

About Apollo

Apollo is a high-growth, global alternative asset manager. We seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid and opportunistic. Through our investment activity across our fully integrated platform, we serve the retirement income and financial return needs of our clients, and we offer innovative capital solutions to businesses. Our patient, creative, knowledgeable approach to investing aligns our clients, businesses we invest in, our employees and the communities we impact, to expand opportunity and achieve positive outcomes. As of March 31, 2021, Apollo had approximately $461 billion of assets under management. To learn more, please visit www.apollo.com.

Contacts

For Investors
Peter Mintzberg, Head of Investor Relations
Apollo Global Management, Inc.
+1 (212) 822-0528
[email protected]

For Media
Joanna Rose, Global Head of Corporate Communications
Apollo Global Management, Inc.
+1 (212) 822-0491

LONDON, July 08, 2021 (GLOBE NEWSWIRE) — Renowned producer, composer and artist John Parish has signed a global deal with Blue Raincoat Music Publishing/Reservoir encompassing all of John’s multi-dimensional work across an incredible 25-year career.

Since the mid-90s John has worked with a range of artists, while also writing for film, stage and TV. He collaborated on five PJ Harvey albums, co-producing and featuring on the Mercury Award-winning Let England Shake and Mercury-nominated To Bring You My Love, and also co-writing and performing on Dance Hall At Louse Point and A Woman A Man Walked By.

Most recently, John produced London band Dry Cleaning’s debut album, New Long Leg, which topped the UK Independent Albums chart. Other productions include Aldous Harding, Sparklehorse, Tracy Chapman, Giant Sand, This Is The Kit and the Eels’ Souljacker, on which he also co-wrote.

Under his own name John released four albums with feted Thrill Jockey label and 2018’s Bird Dog Dante. He has created award-winning scores for many independent movies including Patrice Toye’s Rosie and Little Black Spiders, Ursula Meier’s L’Enfant D’en Haut, and Nathalie Teirlinck’s Le Passé Devant Nous.

Blue Raincoat Music Publishing/Reservoir have also welcomed two fantastic emerging artists to their roster: Elanor Moss and HighSchool.

Elanor Moss, born in Lincolnshire and living in Leeds, is an exciting new artist armed with insightful, truthful, and powerful song-writing. The striking warmth of her voice and effortlessness with which she plays lyrical and complex guitar lines creates a rich musical landscape. Championed by Benjamin Leftwich Francis, Elanor added vocals to his single “Elephant” as well as his forthcoming album. She is currently working on her debut EP due out later in 2021.

Melbourne-based band HighSchool released their debut single “Frosting” in 2020, which saw them sign with UK label Dalliance Records. Singles “New York, Paris and London” and “De Facto” soon followed, all demonstrating how visceral post-punk grit and youthful sophistication can coexist. The band’s melding of low-fi electronica, unflinching guitar and keen-eyed melody, make HighSchool one of the world’s most compelling new bands.

This news comes following the announcement that Reservoir has entered into an agreement with Roth CH II ($ROCC), a special purpose acquisition company, taking the first step toward becoming a publicly traded company listed on the Nasdaq.

About Reservoir


Reservoir is an independent music company based in New York City and with offices in Los Angeles, Nashville, Toronto, London, and Abu Dhabi. Founded as a family-owned music publisher in 2007, the company has grown to represent over 130,000 copyrights and 36,000 master recordings with titles dating as far back as 1900, and hundreds of #1 releases worldwide. Reservoir holds a regular Top 10 U.S. Market Share according to Billboard’s Publishers Quarterly, was twice named Publisher of the Year by Music Business Worldwide’s The A&R Awards, and won Independent Publisher of the Year at the 2020 Music Week Awards.

The company also represents a multitude of recorded music through Chrysalis Records, Tommy Boy Records, and Philly Groove Records and manages artists through its ventures with Blue Raincoat Music and Big Life Management.

VAN BUREN TOWNSHIP, Mich. and BURLINGTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, and Visteon Corporation (NASDAQ: VC), an automotive technology leader dedicated to creating more enjoyable, connected and safe driving experiences, today announced Cerence’s conversational AI will be integrated in Visteon’s recent SmartCore™ product award with a leading motorcycle manufacturer.

The product will include core Cerence^® technologies, including AI-powered voice recognition, natural language understanding, and text-to-speech – all with global language support – alongside Visteon’s Android-based SmartCore™ technology platform: the integrated domain controller powering the instrument cluster, infotainment, telematics, and display. The system will launch with a leading motorcycle manufacturer in 2024, powering a 12-inch display that offers connected apps and over-the-air software download capabilities.

“The motorcycle market is undergoing a digital-cockpit transformation similar to passenger vehicles,” said Bob Vallance, senior vice president, customer business groups and marketing. “Providing our customer with an integrated digital experience technology created by Visteon with Cerence’s technology equips riders with voice-powered access to a dynamic infotainment experience, keeping them safe and informed while on the road.”

This integrated solution can be augmented and expanded to meet the customer’s needs with the addition of other Cerence core technologies, Cerence Cloud Services, and more.

“As two-wheelers become more prevalent, there’s a need for intelligent, voice-powered experiences that help keep riders safe through deep integration with their expansive digital lives,” said Sanjay Dhawan, CEO, Cerence Inc. “The infotainment system is the central brain of these vehicles, and we are proud to partner with Visteon as the leader in cockpit electronics to together create consistent, integrated experiences that can be simply deployed by our mobility customers.”

For more about Visteon, visit www.visteon.com/newsroom/, and follow the company on LinkedIn. To learn more about Cerence, visit www.cerence.com, and follow the company on LinkedIn and Twitter.

About Cerence Inc.

Cerence (NASDAQ: CRNC) is the global industry leader in creating unique, moving experiences for the mobility world. As an innovation partner to the world’s leading automakers and mobility OEMs, it is helping advance the future of connected mobility through intuitive, powerful interaction between humans and their cars, two-wheelers, and even elevators, connecting consumers’ digital lives to their daily journeys no matter where they are. Cerence’s track record is built on more than 20 years of knowledge and more than 350 million cars shipped with Cerence technology. Whether it’s connected cars, autonomous driving, e-vehicles, or buildings, Cerence is mapping the road ahead. For more information, visit www.cerence.com.

About Visteon Corporation

Visteon is a technology leader in automotive electronics dedicated to creating a more enjoyable, connected and safe driving experience. Our platforms leverage proven, scalable hardware and software solutions that enable the digital, electric and autonomous evolution of our global automotive customers. Visteon products align with key industry trends and include digital instrument clusters, displays, Android-based infotainment systems, domain controllers, advanced driver assistance systems (ADAS) and battery management systems. The company is headquartered in Van Buren Township, Michigan, and has approximately 10,000 employees at more than 40 facilities in 18 countries. Visteon reported sales of approximately $2.5 billion and booked $4.6 billion of new business in 2020. Learn more at https://www.visteon.com/newsroom/.

Contact Information

Kate Hickman
Cerence Inc.
Tel: 339-215-4583
Email: [email protected]

Dave Barthmuss
Visteon Corp.
Tel: 805-660-1914
Email: [email protected]

WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 to be held virtually, July 14-15.

Details on the panel can be found below.

Title: Delivery and Durability of Genetic Medicines
Date & Time: Thursday, July 15 at 10:00 a.m. ET

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:

Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
[email protected]

For Media: 

Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
[email protected] 

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (Nasdaq: AWH) today announced its OVA1^® risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health’s Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation’s largest health care organizations. AIM’s mission is to promote appropriate, safe, and affordable health care. As one of the nation’s leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments.

The OVA1^® test is now included in AIM’s guidelines for the preoperative evaluation of an adnexal mass when it is indeterminate based on clinical and complete pelvic ultrasound evaluation. The guidelines also include OVA1^® for the determination of the required surgical approach, operator expertise and level of care for an adnexal mass.

Recent positive coverage additions for OVA1^®, such as New York State Medicaid, coupled with peer-reviewed publications documenting OVA1^®’s superior clinical performance as compared to CA125, especially among Black women, has resulted in a dramatic increase in the number of women who have access to the OVA1^® technology. Aspira Labs, Inc., a subsidiary of Aspira Women’s Health, is the only U.S. provider for Aspira’s proprietary OVA1^® test, an FDA-cleared, ACOG recommended, and Medicare covered ovarian cancer risk assessment tool for women with a pelvic mass.

“We are excited to provide access to OVA1plus^TM, to such a large segment of the population,” said Valerie Palmieri, President and CEO of Aspira Women’s Health Inc. “This guideline from an organization with a robust technology assessment process expands our ability to truly change the standard of care and helps advance our commitment to making OVA1^® accessible to ALL women.”

About Aspira Women’s Health Inc.

Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus^TM combines our FDA-cleared products, OVA1^® and OVERA^®, to detect risk of ovarian malignancy in women with adnexal masses. [Aspira GenetiX^TM] testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are [OVASight^TM and EndoCheck^TM]. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
[email protected]

SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or “the Company”), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced receipt of the 3^rd year award of a multi-year grant from the National Institute on Drug Abuse (NIDA). This award will provide $2.8 million to initiate a Phase 1 study of the first MPAR™ overdose protection product in the U.S., PF614-MPAR. This brings the total support of NIDA to $8.0 million. An additional $2.8 million award for year four is pending.

“We are honored to receive the UH3 award titled ‘PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial’ from the National Institute on Drug Abuse, which provides us with additional resources to continue our work to bring PF614-MPAR™ into clinical development,” said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. “Importantly, our next-generation opioid platform is highly differentiated from currently marketed opioid products and designed to significantly reduce abuse potential and overdose protection. We remain focused on our commitment to stem the prescription drug abuse epidemic and look forward to bringing our unique pipeline of products to the industry, which will ultimately provide safer options for both prescribers and patients.”

PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TAAP) and overdose protection through multi-pill abuse resistance (MPAR™) technology. TAAP chemical modification inactivates the active ingredient in PF614 to provide abuse deterrence, and the combination with the trypsin inhibitor, nafamostat, in MPAR™ provides the additional layer of overdose protection. The MPAR™ overdose protection has been demonstrated in animals and the Phase 1 study with PF614 is being conducted to further validate the MPAR™ overdose protection technology. The Phase 1 study trial, “A Single Dose Study to Evaluate the Pharmacokinetics of oxycodone and PF614, when PF614 Solution is Co-Administered with Nafamostat, as an Immediate Release Solution and/or Extended Release (ER) Capsule Formulations in Healthy Subjects” is being conducted by Dr. Maricer Escalon MD, MS, MBA at Quotient Sciences.

“This award further confirms Ensysce’s important TAAP and MPAR™ technology, which has been recognized by NIH, NIDA and the Federal Government,” said Dr. William Schmidt, Chief Medical Officer of Ensysce. “We remain committed to addressing the significant unmet needs in the marketplace, and look forward to advancing our pipeline of opioid TAAP and MPAR™ products to combat the opioid crisis.”

About Ensysce Biosciences:

Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s definitive proxy statement/prospectus relating to the recently completed business combination with Leisure Acquisition Corp., which is available, free of charge, at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences
Investor Relations Contact:

Gateway Investor Relations
Alex Thompson | Matt Glover
(949) 574-3860
[email protected]